
As New Duchenne Therapy Enters Phase 1 Trial, Advocacy Groups Seek Better Access to Existing Drug
Pfizer has dosed its first patient in a phase 1 clinical trial of an investigational gene therapy for the treatment of patients with Duchenne muscular dystrophy, a genetic disease that results in the absence of dystrophin, a protein that helps to keep muscle cells intact.
Pfizer has dosed its first patient in a phase 1 clinical trial of an investigational gene therapy for the treatment of patients with Duchenne muscular dystrophy (DMD), a
The therapy, PF-06939926, is a recombinant adeno-associated virus capsid carrying a truncated version of the human dystrophin gene under the control of a human muscle-specific promotor.
Enrollment in the multicenter, open-label, nonrandomized ascending dose study is expected to continue at up to 4 research sites in the United States, and early data are expected in the first half of 2019. The study will enroll approximately 12 patients with DMD, aged 5 to 12 years, and will evaluate the safety and tolerability of the drug, dystrophin expression and distribution, and patients’ muscle strength, quality, and function.
“Investment in this trial represents the culmination of years of research on behalf of patients by scientists at Pfizer and academic medical centers, along with the support of the DMD patient advocacy community, in the important quest to advance a program that could potentially change the trajectory of this debilitating disease,”
Current treatments for DMD include the use of corticosteroids and eteplirsen (Exondys 51), a injected drug that
While eteplirsen, currently the only FDA-approved treatment for DMD, has been
As a result of the limited patient access that results from such a high price tag, 6 advocacy organizations, including Patients for Affordable Drugs and Universities Allied for Essential Medicines,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.